Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
GILD · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortGILEAD SCIENCES, INC. is profitable, generates cash and carries moderate debt, with revenue growing (+2.4% last year).
Financial health
Strong
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 34.0% | 100/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 28.9% | 100/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 40.5% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 18.3% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.55× | 63/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.10× | 50/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 1.67× | 67/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 9.79× | 79/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 3.28 | 56/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 32.1% | 100/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 1.11× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 4.7% | 94/100 |
| Operating margin volatility | 12.1% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 2.6% | 31/100 |
|---|---|---|
| EPS growth, 3-year average | 23.0% | 100/100 |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 |
| Cost of revenue | 6,601 | 5,657 | 6,498 | 6,251 | 6,234 |
| Gross profit | 20,704 | 21,624 | 20,618 | 22,503 | 23,209 |
| Research & development | 4,601 | 4,977 | 5,718 | 5,907 | 5,799 |
| Selling, general & admin | 5,246 | 5,673 | 6,090 | 6,091 | 5,774 |
| Operating income | 9,918 | 7,330 | 7,605 | 1,662 | 10,022 |
| Interest expense | 1,001 | 935 | 944 | 977 | 1,024 |
| Pre-tax income | 8,278 | 5,814 | 6,859 | 690 | 9,796 |
| Income tax | 2,077 | 1,248 | 1,247 | 211 | 1,286 |
| Net income | 6,225 | 4,592 | 5,665 | 480 | 8,510 |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Diluted shares (millions) | 1,262 | 1,262 | 1,258 | 1,255 | 1,255 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
3.28 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 6, 2026